-+ 0.00%
-+ 0.00%
-+ 0.00%

Gene One Life Science Faces Delisting After Korea Exchange Review

PUBT·10/29/2026 10:00:30
Listen to the news
Gene One Life Science Faces Delisting After Korea Exchange Review
  • Korea Exchange determined Gene One Life Science met delisting criteria on Oct. 29, 2026, following a listing eligibility review.
  • The company has 15 business days from notification to appeal; the deadline is Nov. 19, 2026.
  • Delisting proceedings will begin following the deadline if no appeal is filed.
  • If an appeal is filed, the exchange’s listing disclosure committee will review delisting within 20 business days of receipt.
  • Trading in the company’s shares remains suspended.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gene One Life Science Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261029800883), on October 29, 2026, and is solely responsible for the information contained therein.